Michael Pearson

Statistics

Publications

Citations

1.1K

H-Index

Active since

2001

Affiliations

Sanford Burnham Prebys Medical Discovery Institute(Current)

Michael Pearson is an author at Sanford Burnham Prebys Medical Discovery Institute specializing in oncology, rituximab-based therapy, and chronic lymphocytic leukemia therapy.

Publications per year

2001–2003

Publications

Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity

John C. Byrd, Timothy J. Murphy, Robin Howard et al. · Journal of Clinical Oncology · 2001 · 511 citations

Pharmacy, Oncology, Pharmacokinetics +15

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction

John C. Byrd, Shinichi Kitada, Ian W. Flinn et al. · Blood · 2002 · 363 citations · Full text

Life Sciences, Immunology, Oncology +13

Apoptotic-Regulatory and Complement-Protecting Protein Expression in Chronic Lymphocytic Leukemia: Relationship to In Vivo Rituximab Resistance

Rajat Bannerji, Shinichi Kitada, Ian W. Flinn et al. · Journal of Clinical Oncology · 2003 · 177 citations

Life Sciences, Immunology, Oncology +17

1–3 of 3